Stockreport

Biomea Fusion Details Icovamenib Diabetes Milestones, Teases BMF-650 Obesity Readouts [Yahoo! Finance]

Biomea Fusion, Inc.  (BMEA) 
PDF Executives from Biomea Fusion (NASDAQ:BMEA) discussed the company's lead diabetes program, icovamenib, and outlined near-term clinical milestones during a recent compan [Read more]